<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377921</url>
  </required_header>
  <id_info>
    <org_study_id>UX001-CL301</org_study_id>
    <nct_id>NCT02377921</nct_id>
  </id_info>
  <brief_title>Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)</brief_title>
  <acronym>GNEM</acronym>
  <official_title>A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sialic Acid Extended-Release Tablets in Patients With GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ultragenyx Pharmaceutical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effect of 6 g/day aceneuramic acid
      extended-release (Ace-ER) treatment of participants with GNEM on upper extremity muscle
      strength (upper extremity composite [UEC] score) as measured by dynamometry.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2015</start_date>
  <completion_date type="Actual">June 9, 2017</completion_date>
  <primary_completion_date type="Actual">June 9, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in UEC Score (Total Force in kg) at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Muscle strength based on the maximum voluntary isometric contraction (MVIC) against a dynamometer was measured bilaterally in the following upper extremity muscle groups: gross grip, shoulder abductors, elbow flexors, and elbow extensors. The UEC is derived from the sum of the average of the right and left total force values (measured in kg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Muscle Strength in the Knee Extensors at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Lower extremity muscle strength in the knee extensors was measured by dynamometry. Bilateral total force was defined as the average of the right and left force values (measured in kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LEC Score (Total Force in kg) at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Muscle strength based on MVIC against a dynamometer was measured bilaterally in the following lower extremity muscle groups: knee flexors, hip flexors, hip extensors, hip abductors and hip adductors. The LEC is derived from the sum of the average of the right and left total force values (measured in kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in GNEM FAS Mobility Domain Score at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Lower extremity use and function was assessed using the Mobility domain of the GNEM-FAS instrument a disease-specific measure developed to assess the functional impact of changes in muscle strength on mobility (reflective of the lower extremities). This mobility score ranges from 0 to 40 with higher scores representing greater mobility.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Lifts in the 30 Second Weighted Arm Lift Test at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Upper extremity function was assessed using a weighted arm lift test performed bilaterally. The number of times the participant can raise a 1 kg weight above the head in a 30-second period was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Number of Stands in the Sit to Stand Test at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Lower extremity function was assessed using a sit-to-stand test. The number of times the participant can rise from a seated to a standing position in a 30-second period was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Meters Walked in the 6MWT at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>The total distance walked (meters) in a 6-minute period was measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percent Predicted Meters Walked in the 6MWT at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>The total distance walked (meters) in a 6-minute period was measured, and the percent predicted distance based on normative data for age and gender was estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in GNEM FAS Upper Extremity Domain Score at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Upper extremity use and function was assessed using the Mobility domain of the GNEM-FAS instrument a disease-specific measure developed to assess the functional impact of changes in muscle strength on mobility (reflective of the upper extremities). This mobility score ranges from 0 to 40 with higher scores representing greater mobility.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Hereditary Inclusion Body Myopathy</condition>
  <condition>Distal Myopathy With Rimmed Vacuoles</condition>
  <condition>Distal Myopathy, Nonaka Type</condition>
  <condition>GNE Myopathy</condition>
  <arm_group>
    <arm_group_label>Aceneuramic Acid Extended-Release (Ace-ER)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ace-ER 6 g/day, divided 3 times per day (TID) for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo TID for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aceneuramic acid extended-release (Ace-ER)</intervention_name>
    <description>tablets for oral use</description>
    <arm_group_label>Aceneuramic Acid Extended-Release (Ace-ER)</arm_group_label>
    <other_name>UX001</other_name>
    <other_name>sialic acid extended-release (SA-ER)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablets for oral use</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18 to 55 years, inclusive

          -  Willing and able to provide written, signed informed consent after the nature of the
             study has been explained, and before any research-related procedures are conducted

          -  Have a documented diagnosis of GNEM, HIBM, distal myopathy with rimmed vacuoles
             (DMRV), or Nonaka disease due to previously demonstrated mutations in the gene
             encoding the GNE/N-acetylmannosamine kinase (MNK) enzyme (genotyping will not be
             conducted in this study)

          -  Able to provide reproducible force in elbow flexors (i.e. two dynamometry force values
             with no more than 15% variability in the dominant arm) at Screening

          -  Able to walk a minimum of 200 meters during the six-meter walk test (6MWT) at
             Screening without the use of assistive devices, including a cane, crutch(es), walker,
             wheelchair or scooter (ankle foot orthosis/orthoses are permitted)

          -  Willing and able to comply with all study procedures

          -  Participants of child‐bearing potential or with partners of child-bearing potential
             who have not undergone a bilateral salpingo‐oophorectomy and are sexually active must
             consent to use a highly effective method of contraception as determined by the site
             investigator (i.e. oral hormonal contraceptives, patch hormonal contraceptives,
             vaginal ring, intrauterine device, physical double-barrier methods, surgical
             hysterectomy, vasectomy, tubal ligation, or true abstinence [when this is in line with
             the preferred and usual lifestyle of the subject], which means not having sex because
             the subject chooses not to), from the period following the signing of the informed
             consent through 3 months after last dose of study drug

          -  Females of childbearing potential must have a negative pregnancy test at Screening and
             be willing to have additional pregnancy tests during the study. Females considered not
             of childbearing potential include those who have been in menopause for at least two
             years, have had tubal ligation at least one year prior to Screening, or who have had a
             total hysterectomy or bilateral salpingo‐oophorectomy

        Exclusion Criteria:

          -  Ingestion of N-acetyl-D-mannosamine (ManNAc), sialic acid (SA), or related
             metabolites; intravenous immunoglobulin (IVIG); or anything that can be metabolized to
             produce SA in the body within 60 days prior to the Screening Visit

          -  History of more than 30 days treatment with SA-ER and/or Sialic Acid Immediate Release
             (SA-IR) in prior clinical trials in the past year

          -  Has had any hypersensitivity to SA or its excipients that, in the judgment of the
             investigator, places the subject at increased risk for adverse effects

          -  Has serum transaminase (i.e. aspartate aminotransferase [AST] or gamma-glutamyl
             transpeptidase [GGT]) levels greater than 3X the upper limit of normal (ULN) for
             age/gender, or serum creatinine of greater than 2X ULN at Screening

          -  Pregnant or breastfeeding at Screening or planning to become pregnant (self or
             partner) at any time during the study

          -  Use of any investigational product or investigational medical device within 30 days
             prior to Screening, or anticipated requirement for any investigational agent prior to
             completion of all scheduled study assessments

          -  Has a condition of such severity and acuity, in the opinion of the investigator, that
             it warrants immediate surgical intervention or other treatment or may not allow safe
             participation in the study

          -  Has a concurrent disease, active suicidal ideation, or other condition that, in the
             view of the investigator, places the subject at high risk of poor treatment compliance
             or of not completing the study, or would interfere with study participation or would
             affect safety
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Alexandrovska&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Réunion - site GHSR</name>
      <address>
        <city>Saint-Pierre</city>
        <state>Reunion</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Myologie GH Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah-Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Milan</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Tyne And Wear</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lochmüller H, Behin A, Caraco Y, Lau H, Mirabella M, Tournev I, Tarnopolsky M, Pogoryelova O, Woods C, Lai A, Shah J, Koutsoukos T, Skrinar A, Mansbach H, Kakkis E, Mozaffar T. A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy. Neurology. 2019 Apr 30;92(18):e2109-e2117. doi: 10.1212/WNL.0000000000006932. Epub 2019 Jan 25.</citation>
    <PMID>31036580</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <results_first_submitted>June 7, 2018</results_first_submitted>
  <results_first_submitted_qc>June 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 9, 2018</results_first_posted>
  <last_update_submitted>June 11, 2019</last_update_submitted>
  <last_update_submitted_qc>June 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GNE Myopathy</keyword>
  <keyword>GNEM</keyword>
  <keyword>HIBM</keyword>
  <keyword>Nonaka</keyword>
  <keyword>Hereditary Inclusion Body Myopathy</keyword>
  <keyword>DMRV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Distal Myopathies</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02377921/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT02377921/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ace-ER 6 g/Day</title>
          <description>Aceneuramic acid extended-release (Ace-ER) 6 g/day, divided 3 times per day (TID) for 48 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo TID for 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement</population>
      <group_list>
        <group group_id="B1">
          <title>Ace-ER 6 g/Day</title>
          <description>Ace-ER 6 g/day, divided TID for 48 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo TID for 48 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.8" spread="7.91"/>
                    <measurement group_id="B2" value="36.2" spread="8.59"/>
                    <measurement group_id="B3" value="35.0" spread="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Upper Extremity Composite (UEC) Score</title>
          <description>Muscle strength based on the maximum voluntary isometric contraction (MVIC) against a dynamometer was measured bilaterally in the following upper extremity muscle groups: gross grip, shoulder abductors, elbow flexors, and elbow extensors. The UEC is derived from the sum of the average of the right and left total force values (measured in kg).</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.99" spread="26.950"/>
                    <measurement group_id="B2" value="56.31" spread="29.287"/>
                    <measurement group_id="B3" value="56.14" spread="27.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Muscle Strength in the Knee Extensors</title>
          <description>Lower extremity muscle strength in the knee extensors was measured by dynamometry. Bilateral total force was defined as the average of the right and left force values (measured in kg).</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.53" spread="9.035"/>
                    <measurement group_id="B2" value="26.65" spread="8.969"/>
                    <measurement group_id="B3" value="26.59" spread="8.951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lower Extremity Composite (LEC) Score</title>
          <description>Muscle strength based on MVIC against a dynamometer was measured bilaterally in the following lower extremity muscle groups: knee flexors, hip flexors, hip extensors, hip abductors and hip adductors. The LEC is derived from the sum of the average of the right and left total force values (measured in kg).</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.52" spread="33.751"/>
                    <measurement group_id="B2" value="55.17" spread="39.324"/>
                    <measurement group_id="B3" value="54.33" spread="36.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy Functional Activities Scale(GNEM-FAS) Mobility Score</title>
          <description>Lower extremity use and function was assessed using the Mobility domain of the GNEM-FAS instrument a disease specific measure developed to assess the functional impact of changes in muscle strength on mobility (reflective of the lower extremities). This mobility score ranges from 0 to 40 with higher scores representing greater mobility.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.38" spread="7.581"/>
                    <measurement group_id="B2" value="26.23" spread="6.403"/>
                    <measurement group_id="B3" value="26.31" spread="6.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stands in Sit-to-Stand Test</title>
          <description>Lower extremity function was assessed using a sit-to-stand test. The number of times the participant can rise from a seated to a standing position in a 30-second period was recorded.</description>
          <units>stands</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.38" spread="4.103"/>
                    <measurement group_id="B2" value="12.58" spread="4.316"/>
                    <measurement group_id="B3" value="12.48" spread="4.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lifts in Weighted Arm Lift Test</title>
          <description>Upper extremity function was assessed using a weighted arm lift test performed bilaterally. The number of times the subject can raise a 1 kg weight above the head in a 30-second period was recorded.</description>
          <units>arm lifts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.50" spread="10.452"/>
                    <measurement group_id="B2" value="28.18" spread="9.824"/>
                    <measurement group_id="B3" value="29.33" spread="10.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Distance Walked in 6-Minute Walk Test (6MWT)</title>
          <description>The total distance walked (meters) in a 6-minute period was measured.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="367.0" spread="115.07"/>
                    <measurement group_id="B2" value="361.2" spread="109.87"/>
                    <measurement group_id="B3" value="364.2" spread="111.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent of Predicted Distance Walked in 6MWT</title>
          <description>The total distance walked (meters) in a 6-minute period was measured, and the percent predicted distance based on normative data for age and gender was estimated. Predicted Six-Minute Walk Test Distance (meters) = 868.8 - (2.99 x Age) – (74.7 x Sex), where Age is baseline age in years, and Sex = 0 for males, and 1 for females.</description>
          <units>percentage of predicted meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.97" spread="15.521"/>
                    <measurement group_id="B2" value="49.87" spread="14.823"/>
                    <measurement group_id="B3" value="49.92" spread="15.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in UEC Score (Total Force in kg) at Week 48</title>
        <description>Muscle strength based on the maximum voluntary isometric contraction (MVIC) against a dynamometer was measured bilaterally in the following upper extremity muscle groups: gross grip, shoulder abductors, elbow flexors, and elbow extensors. The UEC is derived from the sum of the average of the right and left total force values (measured in kg).</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Ace-ER 6 g/Day</title>
            <description>Ace-ER 6 g/day, divided TID for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo TID for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in UEC Score (Total Force in kg) at Week 48</title>
          <description>Muscle strength based on the maximum voluntary isometric contraction (MVIC) against a dynamometer was measured bilaterally in the following upper extremity muscle groups: gross grip, shoulder abductors, elbow flexors, and elbow extensors. The UEC is derived from the sum of the average of the right and left total force values (measured in kg).</description>
          <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" lower_limit="-3.77" upper_limit="-0.74"/>
                    <measurement group_id="O2" value="-2.99" lower_limit="-4.69" upper_limit="-1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5387</p_value>
            <p_value_desc>Generalized estimating equation (GEE) model includes change from Baseline (BL) as dependent variable, visit, treatment and visit by treatment as fixed factors, and BL values, sex, and region as covariates, with compound symmetry covariance structure.</p_value_desc>
            <method>GEE model</method>
            <param_type>Least Squares (LS) Mean Difference</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.61</ci_lower_limit>
            <ci_upper_limit>3.09</ci_upper_limit>
            <estimate_desc>Difference = Ace-ER - placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Muscle Strength in the Knee Extensors at Week 48</title>
        <description>Lower extremity muscle strength in the knee extensors was measured by dynamometry. Bilateral total force was defined as the average of the right and left force values (measured in kg).</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Ace-ER 6 g/Day</title>
            <description>Ace-ER 6 g/day, divided TID for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo TID for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Muscle Strength in the Knee Extensors at Week 48</title>
          <description>Lower extremity muscle strength in the knee extensors was measured by dynamometry. Bilateral total force was defined as the average of the right and left force values (measured in kg).</description>
          <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="-1.19" upper_limit="1.29"/>
                    <measurement group_id="O2" value="0.45" lower_limit="-1.20" upper_limit="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6938</p_value>
            <p_value_desc>GEE model includes change from Baseline as dependent variable, visit, treatment and visit by treatment as fixed factors, and Baseline values, sex, and region as covariates, with compound symmetry covariance structure.</p_value_desc>
            <method>GEE model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.38</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
            <estimate_desc>Difference = Ace-ER - placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LEC Score (Total Force in kg) at Week 48</title>
        <description>Muscle strength based on MVIC against a dynamometer was measured bilaterally in the following lower extremity muscle groups: knee flexors, hip flexors, hip extensors, hip abductors and hip adductors. The LEC is derived from the sum of the average of the right and left total force values (measured in kg).</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Ace-ER 6 g/Day</title>
            <description>Ace-ER 6 g/day, divided TID for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo TID for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LEC Score (Total Force in kg) at Week 48</title>
          <description>Muscle strength based on MVIC against a dynamometer was measured bilaterally in the following lower extremity muscle groups: knee flexors, hip flexors, hip extensors, hip abductors and hip adductors. The LEC is derived from the sum of the average of the right and left total force values (measured in kg).</description>
          <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" lower_limit="-4.49" upper_limit="0.65"/>
                    <measurement group_id="O2" value="-0.44" lower_limit="-3.96" upper_limit="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5023</p_value>
            <p_value_desc>GEE model includes change from Baseline as dependent variable, visit, treatment and visit by treatment as fixed factors, and Baseline values, sex, and region as covariates, with compound symmetry covariance structure.</p_value_desc>
            <method>GEE model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.83</ci_lower_limit>
            <ci_upper_limit>2.86</ci_upper_limit>
            <estimate_desc>Difference = Ace-ER - placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in GNEM FAS Mobility Domain Score at Week 48</title>
        <description>Lower extremity use and function was assessed using the Mobility domain of the GNEM-FAS instrument a disease-specific measure developed to assess the functional impact of changes in muscle strength on mobility (reflective of the lower extremities). This mobility score ranges from 0 to 40 with higher scores representing greater mobility.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Ace-ER 6 g/Day</title>
            <description>Ace-ER 6 g/day, divided TID for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo TID for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in GNEM FAS Mobility Domain Score at Week 48</title>
          <description>Lower extremity use and function was assessed using the Mobility domain of the GNEM-FAS instrument a disease-specific measure developed to assess the functional impact of changes in muscle strength on mobility (reflective of the lower extremities). This mobility score ranges from 0 to 40 with higher scores representing greater mobility.</description>
          <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.49" lower_limit="-3.56" upper_limit="-1.42"/>
                    <measurement group_id="O2" value="-1.77" lower_limit="-2.59" upper_limit="-0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2739</p_value>
            <p_value_desc>GEE model includes change from Baseline as dependent variable, visit, treatment and visit by treatment as fixed factors, and Baseline values, sex, and region as covariates, with compound symmetry covariance structure.</p_value_desc>
            <method>GEE model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.01</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
            <estimate_desc>Difference = Ace-ER - placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Lifts in the 30 Second Weighted Arm Lift Test at Week 48</title>
        <description>Upper extremity function was assessed using a weighted arm lift test performed bilaterally. The number of times the participant can raise a 1 kg weight above the head in a 30-second period was recorded.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Ace-ER 6 g/Day</title>
            <description>Ace-ER 6 g/day, divided TID for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo TID for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Lifts in the 30 Second Weighted Arm Lift Test at Week 48</title>
          <description>Upper extremity function was assessed using a weighted arm lift test performed bilaterally. The number of times the participant can raise a 1 kg weight above the head in a 30-second period was recorded.</description>
          <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
          <units>arm lifts</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-2.19" upper_limit="2.26"/>
                    <measurement group_id="O2" value="2.79" lower_limit="0.21" upper_limit="5.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1235</p_value>
            <p_value_desc>GEE model includes change from Baseline as dependent variable, visit, treatment and visit by treatment as fixed factors, and Baseline values, sex, and region as covariates, with compound symmetry covariance structure.</p_value_desc>
            <method>GEE model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.27</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
            <estimate_desc>Difference: Ace-ER 6 g/day - placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Number of Stands in the Sit to Stand Test at Week 48</title>
        <description>Lower extremity function was assessed using a sit-to-stand test. The number of times the participant can rise from a seated to a standing position in a 30-second period was recorded.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Ace-ER 6 g/Day</title>
            <description>Ace-ER 6 g/day, divided TID for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo TID for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Stands in the Sit to Stand Test at Week 48</title>
          <description>Lower extremity function was assessed using a sit-to-stand test. The number of times the participant can rise from a seated to a standing position in a 30-second period was recorded.</description>
          <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
          <units>stands</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="-0.55" upper_limit="0.77"/>
                    <measurement group_id="O2" value="0.53" lower_limit="-0.21" upper_limit="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3907</p_value>
            <p_value_desc>GEE model includes change from Baseline as dependent variable, visit, treatment and visit by treatment as fixed factors, and Baseline values, sex, and region as covariates, with compound symmetry covariance structure.</p_value_desc>
            <method>GEE model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.40</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
            <estimate_desc>Difference: Ace-ER 6 g/day - placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Meters Walked in the 6MWT at Week 48</title>
        <description>The total distance walked (meters) in a 6-minute period was measured.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Ace-ER 6 g/Day</title>
            <description>Ace-ER 6 g/day, divided TID for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo TID for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Meters Walked in the 6MWT at Week 48</title>
          <description>The total distance walked (meters) in a 6-minute period was measured.</description>
          <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
          <units>meters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.79" lower_limit="-32.09" upper_limit="-3.50"/>
                    <measurement group_id="O2" value="-6.81" lower_limit="-16.83" upper_limit="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1964</p_value>
            <p_value_desc>GEE model includes change from Baseline as dependent variable, visit, treatment and visit by treatment as fixed factors, and Baseline values, sex, and region as covariates, with compound symmetry covariance structure.</p_value_desc>
            <method>GEE model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-10.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.64</ci_lower_limit>
            <ci_upper_limit>5.68</ci_upper_limit>
            <estimate_desc>Difference: Ace-ER 6 g/day - placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percent Predicted Meters Walked in the 6MWT at Week 48</title>
        <description>The total distance walked (meters) in a 6-minute period was measured, and the percent predicted distance based on normative data for age and gender was estimated.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Ace-ER 6 g/Day</title>
            <description>Ace-ER 6 g/day, divided TID for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo TID for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percent Predicted Meters Walked in the 6MWT at Week 48</title>
          <description>The total distance walked (meters) in a 6-minute period was measured, and the percent predicted distance based on normative data for age and gender was estimated.</description>
          <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
          <units>percentage of predicted meters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.37" lower_limit="-4.30" upper_limit="-0.44"/>
                    <measurement group_id="O2" value="-0.97" lower_limit="-2.32" upper_limit="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2241</p_value>
            <p_value_desc>GEE model includes change from Baseline as dependent variable, visit, treatment and visit by treatment as fixed factors, and Baseline values, sex, and region as covariates, with compound symmetry covariance structure.</p_value_desc>
            <method>GEE model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.66</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
            <estimate_desc>Difference: Ace-ER - placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in GNEM FAS Upper Extremity Domain Score at Week 48</title>
        <description>Upper extremity use and function was assessed using the Mobility domain of the GNEM-FAS instrument a disease-specific measure developed to assess the functional impact of changes in muscle strength on mobility (reflective of the upper extremities). This mobility score ranges from 0 to 40 with higher scores representing greater mobility.</description>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Ace-ER 6 g/Day</title>
            <description>Ace-ER 6 g/day, divided TID for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo TID for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in GNEM FAS Upper Extremity Domain Score at Week 48</title>
          <description>Upper extremity use and function was assessed using the Mobility domain of the GNEM-FAS instrument a disease-specific measure developed to assess the functional impact of changes in muscle strength on mobility (reflective of the upper extremities). This mobility score ranges from 0 to 40 with higher scores representing greater mobility.</description>
          <population>Primary Analysis Set: participants who had a Baseline and at least 1 postbaseline measurement.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" lower_limit="-2.21" upper_limit="-0.58"/>
                    <measurement group_id="O2" value="-1.08" lower_limit="-1.86" upper_limit="-0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5608</p_value>
            <p_value_desc>GEE model includes change from Baseline as dependent variable, visit, treatment and visit by treatment as fixed factors, and Baseline values, sex, and region as covariates, with compound symmetry covariance structure.</p_value_desc>
            <method>GEE model</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.39</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
            <estimate_desc>Difference: Ace-ER 6 g/day - placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Screening through Week 48 plus 28 days (+5 days). The mean (SD) duration of treatment was 340.2 (12.02) days and 332.9 (40.86) days for the Ace-ER and placebo groups, respectively.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ace-ER 6 g/Day</title>
          <description>Ace-ER 6 g/day, divided TID for 48 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo TID for 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information</name_or_title>
      <organization>Ultragenyx Pharmaceutical Inc</organization>
      <phone>1-888-756-8567</phone>
      <email>medinfo@ultragenyx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

